huCD33-BsAb (Y-mAbs Therapeutics)

N/A

Report date: 2026/03/19 17:22:23

Base Information

Drug NamehuCD33-BsAb (Y-mAbs Therapeutics)

Drug Alias NameCD33xCD3 Bispecific AntibodyhuCD33-BsAb (CD33xCD3)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-Myeloid cell surface antigen CD33

TargetsT cell surface glycoprotein CD3Myeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesY-Mabs Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A